Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewZ-Cyclopentyl-AP4
Discontinued Product
3249 has been discontinued.
View all Glutamate (Metabotropic) Group III Receptors products.
Description: Group III mGlu agonist (mGlu4 > mGlu8 > mGlu7)
Chemical Name: cis-(±)-1-Amino-3-phosphonocyclopentane carboxylic acid
Purity: ≥98% (HPLC)
Biological Activity for Z-Cyclopentyl-AP4
Z-Cyclopentyl-AP4 is a group III mGlu receptor agonist that exhibits higher potency at mGlu4 than mGlu8 (EC50 values are 49 and 124 μM respectively) with no activity at mGlu7. Selectively inhibits synaptic activity in the lateral perforant pathway (IC50 values are 130 and 1859 μM in the lateral and medial perforant pathways respectively). Conformationally restrained analog of L-AP4 (Cat No. 0103).
Technical Data for Z-Cyclopentyl-AP4
| M. Wt | 209.14 |
| Formula | C6H12NO5P |
| Storage | Store at +4°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 103439-17-4 |
| PubChem ID | 56972223 |
| InChI Key | GLBQBTFFQHNHGC-RPBIHNRISA-N |
| Smiles | [H][C@@]1(CC[C@@](N)(C1)C(O)=O)P(O)(O)=O.[H][C@]1(CC[C@](N)(C1)C(O)=O)P(O)(O)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for Z-Cyclopentyl-AP4
References for Z-Cyclopentyl-AP4
References are publications that support the biological activity of the product.
Crooks et al (1986) Cyclic analogues of 2-amino-4-phosphonobutanoic acid (APB) and their inhibition of hippocampal excitatory transmission and displacement of [3H]APB binding. J.Med.Chem. 29 1988 PMID: 3020251
Ayala et al (2008) Group III mGluR regulation of synaptic transmission at the SC-CA1 synapse is developmentally regulated. Neuropharmacology 54 804 PMID: 18255102
Jones et al (2008) Metabotropic glutamate receptors mGluR4 and mGluR8 regulate transmission in the lateral olfactory tract-piriform cortex synpase. Neuropharmacology 55 440 PMID: 18625254
View Related Products by Target
View Related Products by Product Action
View all Glutamate (Metabotropic) Group III Receptor Agonists
Keywords: Z-Cyclopentyl-AP4, Z-Cyclopentyl-AP4 supplier, Group, III, mGlur, agonists, mGlu4, mGluR4, mGlu8, mGluR8, Receptors, Glutamate, Metabotropic, (Metabotropic), 3249, Tocris Bioscience
Citations for Z-Cyclopentyl-AP4
Citations are publications that use Tocris products.
Currently there are no citations for Z-Cyclopentyl-AP4.
Reviews for Z-Cyclopentyl-AP4
There are currently no reviews for this product. Be the first to review Z-Cyclopentyl-AP4 and earn rewards!
Have you used Z-Cyclopentyl-AP4?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.